Literature DB >> 2882768

Antagonism of vecuronium-induced neuromuscular blockade with edrophonium or neostigmine.

R K Mirakhur, F M Gibson, G G Lavery.   

Abstract

Antagonism of vecuronium-induced neuromuscular blockade was attempted, at varying degrees of spontaneous recovery, with edrophonium 0.5 mg kg-1 or neostigmine 0.05 mg kg-1 in two groups of 20 patients. Neuromuscular blockade was monitored using a train-of-four (TOF) stimulation. Adequate antagonism of neuromuscular blockade, defined as a sustained TOF ratio of 0.7 or more, was attained in all 20 patients given neostigmine and in 13 out of 20 given edrophonium. Five of the remaining seven patients given edrophonium had shown three or less responses to TOF stimulation before antagonism. While the time to onset of the action of edrophonium (22 s) was not significantly shorter than neostigmine (26 s), the time taken to attain a TOF ratio of 0.7 was significantly shorter with edrophonium (67 s compared with 194 s with neostigmine). It is concluded that edrophonium 0.5 mg kg-1 does not consistently antagonize vecuronium-induced neuromuscular blockade, particularly if there are three or less responses to a TOF stimulation present before antagonism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2882768     DOI: 10.1093/bja/59.4.473

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  The current status of edrophonium: have we come "full circle"?

Authors:  A F Kopman
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

Review 2.  Anticholinergic drugs and anaesthesia.

Authors:  R K Mirakhur
Journal:  Can J Anaesth       Date:  1988-09       Impact factor: 5.063

3.  Priming with anti-cholinesterases--the effect of different priming doses of edrophonium.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

4.  Edrophonium antagonism of vecuronium at varying degrees of fourth twitch recovery.

Authors:  Y M Salib; F Donati; D R Bevan
Journal:  Can J Anaesth       Date:  1993-09       Impact factor: 5.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.